Image-guided focal therapy for prostate cancer

Diagnostic and Interventional Radiology

Volumn 20, Issue 6, 2014, Pages 492-497

  Sankineni, Sandeep ^a   Wood, Bradford J ^a   Rais Bahrami, Soroush ^a   Diaz, Annerleim Walton ^a   Hoang, Anthony N ^a   Pinto, Peter A ^a   Choyke, Peter L ^a   Türkbey, Barış ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; CRYOSURGERY; CYBERKNIFE; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; FOCAL LASER ABLATION; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOLOGY; HUMAN; IMAGE GUIDED FOCAL THERAPY; IRREVERSIBLE ELECTROPORATION DEVICE; LASER SURGERY; MINIMALLY INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL MEDICINE; PROSTATE BIOPSY; PROSTATE CANCER; RADIOFREQUENCY ABLATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; TRANSRECTAL ULTRASONOGRAPHY; AGED; BIOPSY; COMPUTER ASSISTED SURGERY; CONFORMAL RADIOTHERAPY; LOW LEVEL LASER THERAPY; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; PULSED RADIOFREQUENCY TREATMENT; TRANSRECTAL HIGH INTENSITY FOCUSED ULTRASOUND;

AGED; BIOPSY; CRYOSURGERY; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; PULSED RADIOFREQUENCY TREATMENT; RADIOTHERAPY, CONFORMAL; SURGERY, COMPUTER-ASSISTED; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84908378641     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2014.14134     Document Type: Review

References (61)

1. Prostate Cancer Home Page. Available at: http://www.cancer.gov/cancertopics/types/prostate. Accessed March 17, 2014.
2. Rais-Bahrami S, Siddiqui MM, Turkbey B, et al. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 2013; 190:1721-1727.
3. Rastinehad AR, Turkbey B, Salami SS, et al. Improving Detection of Clinically Significant Prostate Cancer: MRI/TRUS Fusion-Guided Prostate Biopsy. J Urol 2013 Dec 12. doi: 10.1016/j.uro.2013.12.007. [Epub ahead of print] [CrossRef]
4. Rais-Bahrami S, Turkbey B, Grant KB, Pinto PA, Choyke PL. Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer. Curr Urol Rep 2014; 15:387. [CrossRef]
5. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012; 13:622-632. [CrossRef]
6. Uchida T, Ohkusa H, Yamashita H, et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006; 13:228-233. [CrossRef]
7. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2006; 9:439-443. [CrossRef]
8. Napoli A, Anzidei M, De Nunzio C, et al. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur Urol 2013; 63:395-398. [CrossRef]
9. Lynn JG, Zwemer RL, Chick AJ. The Biological Application of Focused Ultrasonic Waves. Science 1942; 96:119-120. [CrossRef]
10. Bradley WG, Jr. MR-guided focused ultrasound: a potentially disruptive technology. J Am Coll Radiol 2009; 6:510-513. [CrossRef]
11. Hynynen K, Damianou C, Darkazanli A, Unger E, Schenck JF. The feasibility of using MRI to monitor and guide noninvasive ultrasound surgery. Ultrasound Med Biol 1993; 19:91-92. [CrossRef]
12. Cline HE, Hynynen K, Watkins RD, et al. Focused US system for MR imaging-guided tumor ablation. Radiology 1995; 194:731-737. [CrossRef]
13. So AI. HIFU ablation is not a proven standard treatment for localized prostate cancer. Can Urol Assoc J 2011; 5:424-426. [CrossRef]
14. Boutier R, Girouin N, Cheikh AB, et al. Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer. BJU Int 2011; 108:1776-1781. [CrossRef]
15. Ganzer R, Fritsche HM, Brandtner A, et al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. BJU Int 2013; 112:322-329. [CrossRef]
16. Uchida T, Tomonaga T, Shoji S, Kim H, Nagata Y. High-intensity focused ultrasound (HIFU) using Sonablate devices for the treatment of localized prostate cancer: 13-year experience. AIP Conf Proc 2012; 1:293-299. [CrossRef]
17. Sonablate 500. Available at: http://sonacaremedical.com/sonablate-500-high-intensity-focused-ultrasound. Accessed February 10, 2014.
18. Sonablate 450 Regulatory Status. Available at: http://sonacaremedical.com/sonablate-450-regulatory-status. Accessed February 10, 2014.
19. Dickinson L, Hu Y, Ahmed HU, et al. Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. BJU Int 2013; 112:594-601. [CrossRef]
20. Partanen A, Yerram NK, Trivedi H, et al. Magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy of the prostate: a preclinical study with radiological and pathological correlation using customised MRI-based moulds. BJU Int 2013; 112:508-516. [CrossRef]
21. Cooper SM, Dawber RPR. The history of cryosurgery. J R Soc Med 2001; 94:196-201.
22. Copper IS. Cryogenic surgery: a new method of destruction or extirpation of benign or malignant tissues. N Engl J Med 1963; 268:743-749. [CrossRef]
23. De La Taille A, Benson MC, Bagiella E, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: complication rates and biochemical recurrence. BJU Int 2000; 85:281-286. [CrossRef]
24. Tatli S, Acar M, Tuncali K, Morrison PR, Silverman S. Percutaneous cryoablation techniques and clinical applications. Diagn Interv Radiol 2010; 16:90-95.
25. O’Leary M P, Baum NH, Bohnert WW, et al. 2003 American Urological Association Gallup survey: physician practice patterns, cryosurgery/brachytherapy, male infertility, female urology and insurance/professional liability. J Urol 2004; 171:2363-2365. [CrossRef]
26. O’Leary MP, Baum NH, Blizzard R, et al. 2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol 2002; 168:649-652. [CrossRef]
27. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60:3-11. [CrossRef]
28. Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN, Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001; 57:518-523. [CrossRef]
29. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96:1358-1367. [CrossRef]
30. Adler JR, Jr., Chang SD, Murphy MJ, Doty J, Geis P, Hancock SL. The Cyberknife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg 1997; 69:124-128. [CrossRef]
31. History of the Stanford CyberKnife. Available at: http://stanfordhospital.org/clinicsmedServices/COE/cyberknife/history.html. Accessed March 17, 2014.
32. King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat 2003; 2:25-30.
33. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43:1095-1101. [CrossRef]
34. Lee WR. Prostate cancer and the hypofractionation hypothesis. J Clin Oncol 2013; 31:3849-3851. [CrossRef]
35. Ju AW, Wang H, Oermann EK, et al. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. Radiat Oncol 2013; 8:30. [CrossRef]
36. Lloyd-Davies RW, Collins CD, Swan AV. Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years’ experience (1962-1984). Urology 1990; 36:107-111. [CrossRef]
37. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC, Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73:1043-1048. [CrossRef]
38. King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82:877-882. [CrossRef]
39. Prostate Advances in Comparative Evidence. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01584258. Accessed March 17, 2014.
40. MacDougall ND, Dean C, Muirhead R. Stereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than cyberknife? Clin Oncol (R Coll Radiol) 2014; 26:4-9. [CrossRef]
41. Sander S, Beisland HO, Fossberg E. Neodymion YAG laser in the treatment of prostatic cancer. Urol Res 1982; 10:85-86. [CrossRef]
42. Sander S, Beisland HO. Laser in the treatment of localized prostatic carcinoma. J Urol 1984; 132:280-281.
43. Visualase Image-guided Thermal Laser Ablation Technology in Urology. Available at: http://www.visualaseinc.com/prostate-focal-ablation/. Accessed March 17, 2014.
44. Raz O, Haider MA, Davidson SR, et al. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol 2010; 58:173-177. [CrossRef]
45. Stafford RJ, Shetty A, Elliott AM, et al. Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol 2010; 184:1514-1520. [CrossRef]
46. Woodrum DA, Gorny KR, Mynderse LA, et al. Feasibility of 3.0T magnetic resonance imaging-guided laser ablation of a cadaveric prostate. Urology 2010; 75:1514.e1-e6.
47. Oto A, Sethi I, Karczmar G, et al. MR imaging-guided focal laser ablation for prostate cancer: phase I trial. Radiology 2013; 267:932-40. [CrossRef]
48. Lindner U, Davidson S, Fleshner N, et al. Initial results of MR guided laser focal therapy for prostate cancer. J Urol 2013; 189:e227-e8. [CrossRef]
49. Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993; 72:1291-1299. [CrossRef]
50. Tsivian M, Polascik TJ. Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int 2013; 112:526-530. [CrossRef]
51. FDA Grants Prostate IDE Approval for AngioDynamics’ NanoKnife System. Available at: http://investors.angiodynamics.com/releasedetail.cfm?ReleaseID=772028. Accessed March 17, 2014.
52. Pilot Study of NanoKnife for Ablation of Prostate Cancer in Low Risk Patients. Available at: http://clinicaltrials.gov/show/NCT01972867. Accessed March 17, 2014.
53. Pilot Study on Focal Prostate Radio-Frequency Ablation. Available at: http://clinicaltrials.gov/show/NCT01423006. Accessed March 17, 2014.
54. Steyn JH, Smith FW. Nuclear magnetic resonance imaging of the prostate. Br J Urol 1982; 54:726-728. [CrossRef]
55. Steyn JH, Smith FW. Nuclear magnetic resonance (NMR) imaging of the prostate. Br J Urol 1984; 56:679-681. [CrossRef]
56. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186:1818-1824. [CrossRef]
57. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation. Radiology 2010; 255:89-99. [CrossRef]
58. Rosenkrantz AB, Hindman N, Lim RP, et al. Diffusion-weighted imaging of the prostate: Comparison of b1000 and b2000 image sets for index lesion detection. J Magn Reson Imaging 2013; 38:694-700. [CrossRef]
59. Yagci AB, Ozari N, Aybek Z, Duzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol 2011; 17:130-134.
60. Turkbey B, Bernardo M, Merino MJ, Wood BJ, Pinto PA, Choyke PL. MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol 2012; 18:34-45.
61. Del Vescovo R, Pisanti F, Russo V, et al. Dynamic contrast-enhanced MR evaluation of prostate cancer before and after endorectal high-intensity focused ultrasound. Radiol Med 2013; 118:851-862. [CrossRef]